Placebo matching to spesolimab

Phase 3

Placebo matching to spesolimab is one of 17 therapeutic programs targeting Pyoderma Gangrenosum. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pyoderma GangrenosumRecruiting

Pyoderma GangrenosumPhase 3

Recruiting

Competition

Competitive Landscape

18 competitors in Pyoderma Gangrenosum

#DrugCompanyPhaseTrials

Spevigo

Boehringer Ingelheim

Phase 3

2 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 3

Rayos

RRoxane Laboratories

Phase 3

1 4

Cosentyx

Novartis

Phase 2

2 5

Taltz

Eli Lilly

Phase 2

1 6

Tremfya

Johnson & Johnson

Phase 2

1 7

Ilaris

Novartis

Phase 2

1 8

Olumiant

Eli Lilly

Phase 2

1 9

Hyperbaric Oxygen

IIntermountain Health Care, Inc.

Phase 3

1 10

Velsipity

Pfizer

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Pyoderma Gangrenosum

NCT06624670

Clinical

Trials by Indication[1]

Pyoderma Gangrenosum1 trial

A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06624670·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo matching to spesolimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo matching to spesolimab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

Placebo matching to spesolimab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Pyoderma Gangrenosum1 trial

References

Drug Info

Quick Facts

Related News